Table 1.
Clinicopathological characteristics
| Metastatic recurrence cohort (n = 62) | n (%) |
|---|---|
| Age, mean (range) | 46 (31–80) |
| Subtypes at primary diagnosis | |
| ER+/HER2− | 38 (61%) |
| ER+/HER2+ | 13 (21%) |
| ER+/HER2 unknown | 11 (18%) |
| T stage at primary diagnosis | |
| T0 - DCIS | 2 (3%) |
| T1 | 12 (20%) |
| T2 | 33 (53%) |
| T3 | 7 (11%) |
| T4 | 3 (5%) |
| NA | 5 (8%) |
| LN+ at primary diagnosis | |
| Negative | 10 (16%) |
| Positive | 44 (71%) |
| NA | 8 (13%) |
| Chemotherapy for primary breast cancer | |
| Adjuvant | 24 (38%) |
| Neoadjuvant | 26 (42%) |
| Endocrine treatments | |
| Neoadjuvant | 2 (3%) |
| Adjuvant TAM only | 47 (76%) |
| Adjuvant AI/AI + TAM | 14 (23%) |
| Advanced TAM only | 3 (5%) |
| Advanced AI/AI + TAM | 23 (37%) |
| Median follow-up from primary diagnosis, median years (range) | 9.4 (3.3–27.7) |
| Median follow-up from metastasis, years (range) | 3.9 (0.1–15.5) |